Fáddáevttohusat
Čájehuvvojit 1 - 20 oktiibuot 46 bohtosis ohcui ', ohcanáigi: 0,03s Aiddostahte ozu
  1. 1
    SARS-CoV-2 monoclonal antibody testing in vivo

    SARS-CoV-2 monoclonal antibody testing in vivo

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    SARS-CoV-2 variants implications for immunity and vaccine development /

    SARS-CoV-2 variants implications for immunity and vaccine development /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    SARS-COV-2 human monoclonal antibody therapy update

    SARS-COV-2 human monoclonal antibody therapy update

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    The COVID-19 outbreak April 2021 update /

    The COVID-19 outbreak April 2021 update /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Genetic surveillance and the emergence of SARS-CoV-2 variants

    Genetic surveillance and the emergence of SARS-CoV-2 variants

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    SARS-CoV-2 mutations phenotypes and implications for vaccine development /

    SARS-CoV-2 mutations phenotypes and implications for vaccine development /

    Almmustuhtton 2021
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Update on the SNG001 drug, an INFbeta therapy for COVID-19

    Update on the SNG001 drug, an INFbeta therapy for COVID-19

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    The Oxford/AstraZeneca COVID-19 vaccine trial adverse patient event reports /

    The Oxford/AstraZeneca COVID-19 vaccine trial adverse patient event reports /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Imperial College London's saRNA Vaccine - COVAC1

    Imperial College London's saRNA Vaccine - COVAC1

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    The evolutionary origin of SARS-CoV-2

    The evolutionary origin of SARS-CoV-2

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Human challenge trials for vaccines against COVID-19

    Human challenge trials for vaccines against COVID-19

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    The development of SARS-CoV-2 vaccines

    The development of SARS-CoV-2 vaccines

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Remdesivir COVID-19 clinical trial

    Remdesivir COVID-19 clinical trial

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Nanotechnologies in the fight against coronaviruses

    Nanotechnologies in the fight against coronaviruses

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    INFbeta therapy for COVID-19 the new SNG001 drug /

    INFbeta therapy for COVID-19 the new SNG001 drug /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    SARS-CoV-2 human monoclonal antibody therapy

    SARS-CoV-2 human monoclonal antibody therapy

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Development of an intranasal vaccine for SARS-CoV-2

    Development of an intranasal vaccine for SARS-CoV-2

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    COVID-19 epidemiology and potential treatments follow up interview /

    COVID-19 epidemiology and potential treatments follow up interview /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    SARS-COV-2 vaccine current biological targets and considerations /

    SARS-COV-2 vaccine current biological targets and considerations /

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    The current understanding of the biology of the SARS-COV-2 virus

    The current understanding of the biology of the SARS-COV-2 virus

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Series
    Elektrovnnalaš Jietna
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: